In March 2018 it was announced that Agilent Technologies Inc (NYSE:A) had acquired Advanced Analytical Technologies, Inc. (AATI) in an all cash transaction. Until now a privately-held corporation, AATI has developed a rapid microbiology platform to replace the traditional method of growing microbial organisms on agar plates: capillary electrophoresis-based (CE) solutions for fully-automated analysis of a range of molecules. Electrophoresis is a commonly used separation technique to analyze biomolecules such as nucleic acids (RNA and DNA), proteins, carbohydrates and small molecules. With a broad range of applications, the approach is used across a variety of industries, including pharma and biopharma, clinical and diagnostics, food, environmental and forensics, and chemical and energy. Enhancing Agilent's expertise and technology, AATI has developed compelling CE technologies that provide key advances in sensitivity and resolution to address a wide range of applications. AATI solutions are comprised of instruments, software and consumables aimed at simplifying complex workflows. Technology advances in genomics, metabolomics, and proteomics are driving growth and demand for innovative new solutions; for example, AATI has developed optimized screening protocols and QC analysis solutions for CRISPR, an innovative gene-editing technology experiencing rapid growth in development and application.
